Skip to main content
. 2014 Apr 2;2014:282815. doi: 10.1155/2014/282815

Figure 3.

Figure 3

Progression-free survival according to Gravendeel et al. [8] and Verhaak et al. [7] molecular subtypes. GBMs assigned to IGS-18 (dashed line) had a shorter PFS after bevacizumab/irinotecan than those assigned to IGS-22 and IGS-23 (plain line) (3.2 months versus 9.4 months, P = 0.01). GBMs classified as classical (dashed line) had a shorter PFS than those classified as nonclassical (2.2 months versus 8.3 months, P = 0.003).